Alzheimer's Drugs Remove Amyloid but Show No Meaningful Patient Benefits in 18 Months

A major review published Thursday challenges the effectiveness of highly publicized Alzheimer's disease drugs, finding that while these medications successfully removed amyloid buildup in the brain, they failed to produce meaningful clinical improvements in patients over an 18-month period. The drugs, once heralded as breakthrough treatments, have faced scrutiny for their limited real-world impact despite their ability to target the underlying amyloid pathology. However, some medical experts have criticized the review's methodology and conclusions. This finding raises important questions for Alzheimer's patients and families considering these expensive treatments about the actual benefits they can expect.